| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.36 | 2e-25 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.34 | 2e-25 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.33 | 5e-21 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.38 | 2e-16 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.26 | 1e-13 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.35 | 2e-11 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.22 | 2e-11 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.31 | 3e-10 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.21 | 8e-10 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | 0.21 | 1e-09 |